Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00441090 · ClinicalTrials.gov registry record · Phase 2
Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT00441090 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 64 participants.
The verdict
NCT00441090, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy, safety and tolerability, of AKR-501 (avatrombopag) tablets, as compared to placebo, in the treatment of participants with chronic Idiopathic Thrombocytopenic Purpura (ITP).
Interventions
- DRUG Placebo
- DRUG Avatrombopag tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00441090
The ClinicalTrials.gov registry entry for NCT00441090 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00441090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00441090 about?
NCT00441090 is a clinical study titled "Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)". The purpose of this study is to determine the efficacy, safety and tolerability, of AKR-501 (avatrombopag) tablets, as compared to placebo, in the treatment of participants with chronic Idiopathic Thrombocytopenic Purpura (ITP).
What is the current status of trial NCT00441090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2007-02. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00441090?
The interventions under investigation include: Placebo (DRUG), Avatrombopag tablets (DRUG).
Who is sponsoring clinical trial NCT00441090?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.